Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

471.12 -4.86 (-1.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
53 54 Next >
2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade
These stocks are growing steadily and have a solid history of enriching shareholders. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in February
Going with these stocks should be an easy decision. 
Via The Motley Fool
The 10 Best Stocks to Buy in February 2023
These diversified growth stocks could add rocket fuel to your long-term investing portfolio. 
Via The Motley Fool
A New Bull Market Could Arrive in February: 3 Stocks to Buy Now
The bulls could be about to take over again. And these stocks are poised to be big winners. 
Via The Motley Fool
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,600 Today
Via Benzinga
3 Things About CRISPR Therapeutics That Smart Investors Know
The gene-therapy specialist's near-term outlook is quite bullish. 
Via The Motley Fool
The Best Stocks to Invest $20,000 in Right Now
These healthcare giants have plenty of room left to run. 
Via The Motley Fool
The Latest Analyst Ratings for Vertex Pharmaceuticals
Via Benzinga
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
These companies have the therapies to boost revenue for a decade. 
Via The Motley Fool
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
7 Cream-of-the-Crop Stocks to Buy Today
Fast-growing, underappreciated stocks to buy are trading at a steep discount and will reward investors as they rise in value. 
Via InvestorPlace
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength. 
Via Talk Markets
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies. 
Via The Motley Fool
5 Reasons to Buy Vertex Pharmaceuticals Now
Vertex shares are extending last year's gains, and that trend probably isn't over. 
Via The Motley Fool
3 Dirt Cheap Stocks to Buy in January
Bargains can easily be found as the new year gets underway. 
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Vertex is heading for a new phase of growth. 
Via The Motley Fool
BP Stock, Baidu Lead 5 Stocks Near Buy Points With Big Growth Potential
BP and Chinese search leader Baidu lead this weekend's watch list. 
Via Investor's Business Daily
3 Smart Stocks to Buy if a Recession Is on the Way
Their products will enjoy strong demand regardless of what happens with the economy. 
Via The Motley Fool
The Best Stocks to Invest $5,000 In Right Now
It's still a great time to be a long-term investor. 
Via The Motley Fool
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
The healthcare industry isn't going anywhere. 
Via The Motley Fool
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before. 
Via Investor's Business Daily
3 Unstoppable Stocks to Keep Buying in 2023
These companies have what it takes to drive long-term share performance. 
Via The Motley Fool
Vertex Pharmaceuticals Stock Meets 80-Plus Relative Strength Rating Benchmark
Putting together your watch list? Look for stocks with an 80-plus RS Rating. Vertex Pharmaceuticals stock meets that criteria, rising to 84. 
Via Investor's Business Daily
7 Biotech Stocks That Will Make You Rich in 10 Years
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023
Via Benzinga
Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Biopharma Stocks That Could Help Make You a Fortune
All three are protected by sales of in-demand products, with more on the way. 
Via The Motley Fool
2 Stocks Down More Than 25% to Buy Right Now
These companies are set for a new era of growth. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.